Scientists probe gene link to rare brain disease after infections
NCT ID NCT06731790
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how a specific gene mutation (RANBP2) affects the immune system in people with Acute Necrotizing Encephalopathy type 1 (ANE1), a rare brain condition triggered by infections. Researchers compared blood samples from 35 participants, including patients with the mutation and healthy controls, to measure inflammatory markers. The goal is to better understand why some people develop severe brain inflammation, which could guide future research into treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal why some people with a RANBP2 mutation develop severe brain inflammation after common infections, pointing toward future treatments.
- What could go wrong
- This is a small, early-stage study with only 35 participants, focused on understanding the disease rather than testing a treatment. Results may not apply to all patients or lead directly to therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
35 people
The number who actually took part.
- Started
-
Apr 2025
- Finished
-
Sep 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
1 year to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Obtaining written consent from adult participants * Obtaining written consent from legal guardians of minors with their assent * Subjects aged 1 to 90 * Subject with a T585M mutation in RANBP2 for the RANBP2 mutation arm. * Subjects matched on age (+/- 10 years) and gender for the "control" arm. Exclusion Criteria: * Patient not affiliated to a social security scheme or not a beneficiary of such a scheme. (for example, a European Health Insurance Card (EHIC)) * Absence of written informed consent * Person unable to give consent * legally protected adult (guardianship, curatorship) * Person deprived of liberty * Person participating in another research study with an exclusion period still in progress
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute necrotizing encephalopathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Gui de Chauliac
Montpellier, Hérault, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.